Cyteir Therapeutics, Inc. CYTT
3.01
0.00
0.00%
as of 31 May
- Market cap
- $108.7M
- P/E
- 0.0×
Follow CYTT
Growth Flags
show if company had growth for consecutive years
| Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 | — |
P/S ratio |
— | — | — | 0.00 | — |
P/FCF ratio |
— | — | — | 0.00 | — |
P/Operating CF |
— | — | — | (5.88) | — |
P/B ratio |
— | — | — | 0.20 | — |
Price to Tangible BV |
— | — | — | 0.20 | — |
EV/Sales |
— | — | — | 0.00 | — |
EV/EBITDA |
— | — | — | 6.73 | — |
EV/Operating CF |
— | — | — | 6.11 | — |
EV/FCF |
— | — | — | 5.87 | — |
Quick Ratio |
27.68 | 25.26 | 3.49 | 14.71 | — |
Current Ratio |
28.07 | 25.71 | 3.87 | 15.43 | — |
Net Debt/EBITDA |
3.10 | 4.54 | 0.53 | 1.83 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.92 | 0.86 | 0.89 | 1.17 | — |
Capex/Depreciation |
(0.47) | (2.48) | (2.42) | 0.00 | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | — |
| (27.62%) | (60.50%) | 54.53% | 39.40% | — | |
| (26.42%) | (40.29%) | (92.33%) | (95.92%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(31.64%) | (22.45%) | (202.54%) | (51.43%) | — |
Average Days of Receivables |
— | — | — | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 159,600.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 39,125.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | — |
Graham Net Nets |
— | — | — | 4.94 | — |
Graham Number |
— | — | — | 0.00 | — |
Earnings Yield |
— | — | — | (64.65%) | — |
Free Cash Flow Yield |
— | — | — | (69.25%) | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(1.21) | (1.85) | (12.11) | (3.99) | — |
Capex per Share |
(0.01) | (0.06) | (0.56) | 0.00 | — |
Free Cash Flow per Share |
(1.21) | (1.91) | (12.66) | (3.99) | — |
Cash per Share |
4.17 | 9.73 | 7.14 | 6.60 | — |
Shareholders Equity per Share |
4.15 | 9.61 | (31.37) | 6.61 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
4.15 | 9.61 | (31.37) | 6.61 | — |
Free Cash Flow |
(42.84) | (37.22) | (19.39) | (17.56) | — |
Working Capital |
143.89 | 185.57 | 8.99 | 28.47 | — |
Capital Expenditures |
(0.31) | (1.19) | (0.85) | (0.13) | — |
Net Current Asset Value |
142.26 | 184.98 | (49.63) | 28.14 | — |
EV/EBIT |
— | — | — | 0.00 | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | — |
Net Profit Margin |
0.00% | 0.00% | 0.00% | (188,050.00%) | — |
Price to Operating Income |
— | — | — | 0.00 | — |
| Other line items | |||||
Depreciation/Fixed assets |
0.39 | 0.23 | 0.27 | 0.27 | — |
Cash ROIC |
(15.08%) | (10.10%) | 53.45% | (31.58%) | — |
Accounts Receivable Turnover |
— | — | — | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.19 | — |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 1,022.00 | — |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | — |
Average Payables |
1.46 | 1.74 | 1.15 | 1.15 | — |
Average Assets |
174.31 | 104.56 | 22.55 | 15.68 | — |
Average Common Equity |
166.79 | 69.63 | (38.18) | (38.18) | — |
Columns are period end dates